Publication: Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD)
Open/View Files
Date
2012
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Bochner, Bruce S., Wendy Book, William W. Busse, Joseph Butterfield, Glenn T. Furuta, Gerald J. Gleich, Amy D. Klion, et al. 2012. Workshop Report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). Journal of Allergy and Clinical Immunology 130, no. 3: 587–596. doi:10.1016/j.jaci.2012.07.024.
Research Data
Abstract
BACKGROUND: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human "eosinophil-associated" diseases remain obscure. OBJECTIVE: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. METHODS: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. RESULTS: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. CONCLUSIONS: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.
Description
Other Available Sources
Keywords
eosinophil, apoptosis, therapeutics, research, discovery, fusion oncoproteins, hypereosinophilic syndromes, Churg-Strauss syndrome, coagulopathy
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service